Compare AFLAC Incorporated (AFL) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Amphastar Pharmaceuticals Inc — how do they compare? AFLAC Incorporated trades at $122.08 (market cap $61.13B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: AFLAC Incorporated is far larger — about 70.8× Amphastar Pharmaceuticals Inc's market cap, and AFLAC Incorporated pays a 2% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AFL | AMPH | |
|---|---|---|
Market Cap | $61.13B | $863.95M |
Sector | Financials | Health |
52-Week High | $129.55 | $30.81 |
52-Week Low | $103.55 | $16.87 |
Enterprise Value | $71.08B | $1.26B |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $124.61, down 1.62% with recent earnings misses and bearish technical signals. The stock shows mixed fundamentals with a P/E of 13.44 and net income margin of 26.79%, though revenue declined to $17.36B in 2025. Recent news highlights Japan unit challenges and dividend reliability, with the company maintaining 43 consecutive years of dividend increases.
Outlook remains cautious with analyst consensus at Hold (56.24%) and price target of $117.60 below current levels. Key risks include foreign exchange headwinds and competitive pressures, while the dividend yield and strong cash flow provide support for income-focused investors amid near-term volatility.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
